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Abstract: Genetic testing for BRCA1 and BRCA2 genes has led to the identification of many unique
variants of uncertain significance (VUS). Multifactorial likelihood models that predict the odds ratio
for VUS in favor or against cancer causality, have been developed, but their use is conditioned by
the amount of necessary data, which are difficult to obtain if a variant is rare. As an alternative,
variants mapping to the coding regions can be examined using in vitro functional assays. BRCA1
and BRCA2 proteins promote genome protection by interacting with different proteins. In this study,
we assessed the functional effect of two sets of variants in BRCA genes by exploiting the green
fluorescent protein (GFP)-reassembly in vitro assay, which was set-up to test the BRCA1/BARD1,
BRCA1/UbcH5a, and BRCA2/DSS1 interactions. Based on the findings observed for the validation
panels of previously classified variants, BRCA1/UbcH5a and BRCA2/DSS1 binding assays showed
100% sensitivity and specificity in identifying pathogenic and non-pathogenic variants. While the
actual efficiency of these assays in assessing the clinical significance of BRCA VUS has to be verified
using larger validation panels, our results suggest that the GFP-reassembly assay is a robust method
to identify variants affecting normal protein functioning and contributes to the classification of VUS.
Keywords: hereditary breast/ovarian cancer; BRCA1; BRCA2; variant of uncertain significance;
functional assays; protein-protein interaction
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1. Introduction
Genetic testing for the breast cancer susceptibility genes, BRCA1 (MIM# 113705) and BRCA2
(MIM# 600185), has become part of routine clinical care for patients with a personal or family history
indicative of Hereditary Breast/Ovarian Cancer Syndrome (HBOC). A recent prospective study
estimates the average cumulative risks by age 70 years of BRCA1 carriers to be 60% and 59% for breast
and ovarian cancer, respectively. For BRCA2 carriers, the corresponding values are 55% and 16.5%,
respectively [1]. Most pathogenic variants identified in the BRCA1 and BRCA2 genes are nonsense
or frameshift that, by introducing a premature termination codon, lead to non-functional proteins.
Splice site variants with a similar effect on the protein have also been identified [2]. In addition to these
clearly loss-of-function alterations, a growing number of variants of uncertain significance (VUS) are
currently being identified. These include missense substitutions, small in-frame deletions or insertions,
alterations of both exonic and intronic sites potentially affecting splicing, and variants in regulatory
sequences. The inability to classify the VUS either as disease causing or as rare non-pathogenic (benign)
variation represents a challenge for genetic counselling, risk evaluation, and adoption of preventive
and risk-reduction measures.
A five-tier classification scheme has been developed for the assessment of the clinical relevance
of VUS by the International Agency for Research on Cancer (IARC) Working Group [3]. According
to this scheme, Class 1 (posterior probability of pathogenicity < 0.001) and Class 2 (0.001 < posterior
probability < 0.049) are considered non-pathogenic and likely non-pathogenic variants, Class 3 (0.05 <
posterior probability < 0.949) VUS remain unclassified because of a lack of sufficient information for
classification, Class 4 (0.95 < posterior probability < 0.99) and Class 5 (posterior probability > 0.99) are
likely pathogenic and pathogenic variants, respectively. Posterior probability may be estimated using
a multi-factorial model. For missense variants, this model combines a prior probability of causality,
based on the amino acid evolutionary conservation model (A-GVGD, URL: http://agvgd.iarc.fr/) [4],
with a likelihood ratio for causality derived from genetic and family-based data and histopathological
tumor features [5–8]. However, since most BRCA1 and BRCA2 VUS are detected in a single or a few
families only, this model is not able to classify the majority of them. Therefore, functional assays have
been developed to independently classify VUS based on their effect on established functions of the
BRCA1 and BRCA2 proteins [9,10].
Mounting evidence implicates both BRCA1 and BRCA2 proteins in all phases of the cell cycle
and in the regulation of its orderly events [11] through their association with different proteins [12,13].
As a consequence, a defective protein-protein interaction may lead to uncontrolled cell replication and
genomic instability, which are both hallmarks of tumor formation and progression. Thus, biochemical
in vitro assays analyzing the formation of protein complexes provide a context in which to assess the
functional effect of the BRCA1 [14,15] and BRCA2 VUS [16–18].
One of the most important BRCA1-interacting proteins is BARD1 (MIM# 601593).
Under physiological conditions, BRCA1 is prevalently found to be associated with BARD1.
This interaction is mediated by the N-terminal RING-finger domains of both proteins [19],
which suggests that the heterodimer is the physiological relevant form of BRCA1 and the two proteins
require each other for most of their cellular functions. Several lines of evidence support this view:
BRCA1-BARD1 binding appears to stabilize BRCA1 protein expression [20] and to increase its nuclear
accumulation by masking the nuclear export sequence (NES) flanking the RING-finger domain [21].
The two proteins co-localize in nuclear dots during the S-phase of the cell cycle and in nuclear foci
at sites of DNA damage [22–25]. Most importantly, the binding with the E2 ubiquitin-conjugating
enzyme UbcH5a (MIM# 602961) enables the BRCA1-BARD1 complex to acquire an ubiquitin ligase
activity, linked to BRCA1 tumor suppression function by regulating transcription and double stand
break (DSB) repair [26–28]. This is consistent with the reported hypersensitivity to Ionizing Radiation
(IR) and to agent crosslinking the DNA, such as Cisplatin or Mitomycin C (MMC), of cells carrying
BRCA1 RING pathogenic variants [29–31].
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Concerning BRCA2, the strong physical interaction with the small (70-residues) DSS1 peptide
(MIM# 601285), through its highly conserved C-terminal DSS1/ssDNA Binding Domain (DBD),
appears to be crucial for the maintenance of its stability and correct conformation [32,33], for the repair
of DNA DSBs by homologous recombination (HR) and the formation of DNA damage induced RAD51
foci [34]. Recently, it was shown that the nuclear retention of BRCA2 is regulated by DSS1 interaction
through the masking of a NES, such that variation impairing BRCA2-DSS1 binding mis-localizes
BRCA2 to the cytoplasm [35].
In this study, we analyzed the effect of a group of VUS mapped to the BRCA1 and BRCA2 gene
regions encoding the RING-finger domain of BRCA1 and the DBD of BRCA2 on the binding with
the interacting proteins BARD1, UbcH5a, and DSS1, using the previously established GFP-fragment
reassembly screening [15,36]. In this assay, the GFP is dissected into two fragments (NfrGFP and
CfrGFP) that, when expressed together in E. coli bacterial cells, do not spontaneously reassemble
into a fluorescence protein. However, if each of the two fragments of the GFP are individually
fused to two interacting protein domains, this interaction can mediate the reassembly of the GFP
in co-transformed bacteria with consequent cellular fluorescence. We evaluated the performance of
these approaches in correctly discriminating between pathogenic and non-pathogenic analysis of a
panel of variants classified according to the IARC 5-class model (Leiden Open Variation Database,
URL: http://hci-exlovd.hci.utah.edu/variants.php). In addition, we verified the consistency of the
VUS classification with the results of other published functional analyses investigating the same
variants [14,30,37–50].
2. Results
2.1. Selection of the BRCA1 and BRCA2 Variants
We selected a total of 58 BRCA1 (n = 36) and BRCA2 (n = 22) variants mapping to the gene
regions coding for the conserved motifs encompassing the RING-finger domain of BRCA1 and
the DBD of BRCA2 [13] (Figure 1). Of these, 28 BRCA1 (n = 13) and BRCA2 (n = 15) variants,
classified by the IARC-5 class system as pathogenic or non-pathogenic, were used for assay validation
(Table 1). Thirty BRCA1 (n = 23) and BRCA2 (n = 7) variants were VUS (Table 2) of which 21 were
identified among families referred for BRCA gene testing. Of the remaining nine variants, seven were
extracted from the ClinVar database (https://www.ncbi.nlm.nih.gov/clinvar/), while two, p.Cys27Ala
and p.His41Ala, were synthetic variants not yet observed in HBOC patients and were included so
that at least one variant was examined for each of the critical cystein and histidine residues of the
RING domain.
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Figure 1. Diagram showing the location of specific motifs of the BRCA1 and BRCA2 proteins and the 
variants analyzed. Non-pathogenic variants (class 1 and class 2) are shown in green, pathogenic 
variants (class 4 and class 5) are shown in red, and VUS are shown in black. DBD, DNA binding 
domain. HD, helical domain. OB1, oligonucleotide/oligosaccharide binding fold 1. VUS, variants of 
uncertain significance.
Figure 1. Diagram showing the location of specific motifs of the BRCA1 and BRCA2 proteins and
the variants analyzed. Non-pathogenic variants (class 1 and class 2) are shown in green, pathogenic
variants (class 4 and class 5) are shown in red, and VUS are shown in black. DBD, DNA binding
domain. HD, helical domain. OB1, oligonucleotide/oligosaccharide bi ding fold 1. VUS, variants of
uncertain significance.
Table 1. Variants of validation panels.
Gene DNA Change ProteinChange Domain Motif IARC Class
a References/Criterion
BRCA1
c.53T>C p.Met18Thr RING finger Helical bundle N 4 [6]
c.65T>C p.Leu22Ser RING finger Helical bundle N 5 [51]
c.110C>A p.Thr37Lys RING finger β-Sheet 5 [51]
c.115T>C p.Cys39Arg RING finger Zn2+/SiteII 5 [51]
c.116G>A p.Cys39Tyr RING finger Zn2+/SiteII 5 [52]
c.122A>G p.His41Arg RING finger Zn2+/SiteII 5 [53]
c.130T>A p.Cys44Ser RING finger Zn2+/SiteI 5 [51]
c.131G>T p.Cys44Phe RING finger Zn2+/SiteI 5 [52]
c.131G>A p.Cys44Tyr RING finger Zn2+/SiteI 5 [51]
c.133A>C p.Lys45Gln RING finger 1 [51]
c.181T>G p.Cys61Gly RING finger Zn2+/SiteII 5 [54]
c.191G>A p.Cys64Tyr RING finger Zn2+/SiteII 5 [52]
c.199G>T p.Asp67Tyr RING finger 1 [6]
BRCA2
c.7469T>C p.Ile2490Thr DBD HD 1 Frequency >1% inoutbred populations
c.7544C>T p.Thr2515Ile DBD HD 1 [55]
c.7826G>A p.Gly2609Asp DBD HD 4 [8,47]
c.7878G>C p.Trp2626Cys DBD HD 5 [6]
c.7879A>T p.Ile2627Phe DBD HD 5 [6]
c.7940T>C p.Leu2647Pro DBD HD 4 [46]
c.7958T>C p.Leu2653Pro DBD HD 5 [6,46]
c.8063T>C p.Leu2688Pro DBD OB1 4 [47]
c.8149G>T p.Ala2717Ser DBD OB1 1 [55]
c.8165C>G p.Thr2722Arg DBD OB1 5 [6,46]
c.8167G>C p.Asp2723His DBD OB1 5 [5,8]
c.8168A>G p.Asp2723Gly DBD OB1 5 [6,47,56]
c.8187G>T p.Lys2729Asn DBD OB1 1 [6,8]
c.8243G>A p.Gly2748Asp DBD OB1 5 [6,8]
c.8324T>G p.Met2775Arg DBD OB1 2 [52]
a Class 1/2, non pathogenic/likely non pathogenic, respectively. Class 4/5, likely pathogenic/pathogenic,
respectively. Abbreviations: DBD, DNA binding domain. HD, helical domain. OB1, oligonucleotide/oligosaccharide
binding fold 1.
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Table 2. List of selected BRCA1 and BRCA2 VUS.
Gene DNA Change Protein Change Domain Motif Source ClinVar
BRCA1
c.20_28del9 p.7-10delinsGln RING finger INT VUS (1)
c.43A>G p.Ile15Val RING finger Helical bundle N INT NR
c.44T>C p.Ile15Thr RING finger Helical bundle N INT VUS (4)
c.53T>A p.Met18Lys RING finger Helical bundle N ClinVar VUS (2)
c.70T>C p.Cys24Arg RING finger Zn2+/SiteI ClinVar VUS (1); LP (1), P (1)
c.79_80delTGinsGC p.Cys27Ala RING finger Zn2+/SiteI Synthetica NR
c.83T>C p.Leu28Pro RING finger INT VUS (4)
c.93C>G p.Ile31Met RING finger INT LB (1), VUS (2)
c.100C>T p.Pro34Ser RING finger Rigshospitalet VUS (2)
c.107C>A p.Ser36Tyr RING finger β-strand ICO VUS (5)
c.110C>G p.Thr37Arg RING finger β-strand ClinVar LP (1)
c.115T>G p.Cys39Gly RING finger Zn2+/SiteII Rigshospitalet VUS (1), LP (1), P (1)
c.121_122delCAinsGC p.His41Ala RING finger Zn2+/SiteII Synthetic a NR
c.124A>G p.Ile42Val RING finger Clinvar 3 LB (1), VUS (3)
c.139T>G p.Cys47Gly RING finger Zn2+/SiteI Clinvar LP (1), P (6)
c.143T>G p.Met48Arg RING finger Central Helix Rigshospitalet NR
c.143T>A p.Met48Lys RING finger Central Helix INT NR
c.190T>G p.Cys64Gly RING finger Zn2+/SiteII Clinvar VUS (1), P (11)
c.190T>C p.Cys64Arg RING finger Zn2+/SiteII INT VUS (1), P (4)
c.206_207delCCinsTG p.Thr69Met RING finger INT NR
c.230C>T p.Thr77Met RING finger INT VUS (6)
c.248T>G p.Val83Gly RING finger Helical bundle C ICO NR
c.293G>T p.Gly98Val RING finger INT NR
BRCA2
c.7505G>A p.Arg2502His DBD HD INT B (1), LB (5), VUS (3)
c.7628A>G p.Tyr2543Cys DBD HD INT VUS (7)
c.7636T>C p.Ser2546Pro DBD HD INT VUS (1)
c.7649T>C p.Ile2550Thr DBD HD Clinvar B (1)
c.7684T>C p.Phe2562Leu DBD HD INT VUS (6)
c.7698T>G p.Asp2566Glu DBD HD INT NR
c.7930A>G p.Asn2644Asp DBD HD INT VUS (3)
a [38]. Abbreviations: DBD, DNA binding domain. HD, helical domain, INT, Fondazione IRCCS Istituto Nazionale
dei dei Tumori (Milan, Italy), ICO, Catalan Institute of Oncology (Hospitalet de Llobregat, Barcelona, Spain).
Rigshospitalet (Copenhagen, Denmark). Clinvar, URL: https://www.ncbi.nlm.nih.gov/clinvar/. VUS, variants of
uncertain significance. NR, not reported. LP, likely pathogenic. P, pathogenic. LB, likely benign. B, benign.
2.2. Evaluation of the Effect of BRCA1 Variants on the Interaction with the BARD1 and the UbcH5a Proteins
by the GFP-Reassembly Assay
The N-terminal RING domain (aa 1–109) mediates the E3-ubiquitin ligase activity of BRCA1.
It consists of a RING finger motif (aa 23–76) and two flanking α helices. It is characterized by a
conserved pattern of seven cysteine and one histidine residues, which form two Zn2+-binding sites
(termed Site I and Site II) stabilizing the RING structure. The RING finger motif assembles in a globular
structure with three strand β-sheet and a central helix.
All 36 mutant constructs were co-transformed in bacterial cells with the pET11a-NfrGFP-BARD1
and pET11a-NfrGFP-UbcH5a constructs expressing the wild-type BARD1 (BDN) and UbcH5a
(UbN) proteins, which is in frame with the N-terminal fragment of the GFP protein, respectively.
In addition, pET11a-NfrGFP-BARD1 and pET11a-NfrGFP-UbcH5a were co-transformed with
pMRBAD-BRCA1-CfrGFP expressing wild-type BRCA1 (BR1C) and pMRBAD-Z-CfrGFP expressing
the leucine zipper (Z) peptide (ZC), both in a frame with the C-terminal fragment of the GFP protein,
as positive and non-cognate negative controls. The results are listed in Table 3.
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c.53T>C p.Met18Thr Helical bundle N C45 4 + (also in c) − − − − − − − − − − − − LOF
c.65T>C p.Leu22Ser Helical bundle N C65 5 − − ND ND ND ND ND ND ND ND ND + − LOF
c.110C>A p.Thr37Lys C65 5 + − ND ND ND ND ND ND ND ND ND − ND LOF
c.115T>C p.Cys39Arg Zn2+/SiteII C65 5 − − − ND ND ND ND ND ND ND ND − ND LOF
c.116G>A p.Cys39Tyr Zn2+/SiteII C65 5 − − − − − ND ND − ND − − − − LOF
c.122A>G p.His41Arg Zn2+/SiteII C25 5 + − − ND − ND ND ND ND − − + − LOF
c.130T>A p.Cys44Ser Zn2+/SiteI C65 5 − − ND ND ND ND ND ND ND ND ND − − LOF
c.131G>A p.Cys44Tyr Zn2+/SiteI C65 5 − − ND ND ND ND ND − − ND ND − ND LOF
c.131G>T p.Cys44Phe Zn2+/SiteI C65 5 − − − ND − ND ND ND ND − − − − LOF
c.133A>C p.Lys45Gln C0 1 + + ND ND ND + ND ND ND ND ND + + FUNC
c.181T>G p.Cys61Gly Zn2+/SiteII C65 5 − − − − − − − + − − ND − − LOF
c.191G>A p.Cys64Tyr Zn2+/SiteII C65 5 − − − ND ND ND ND ND ND ND ND − ND LOF




c.20_28del9 p.7-10delinsGln NA NA − − ND ND ND ND ND ND ND ND ND ND ND ND
c.43A>G p.Ile15Val Helical bundle N C15 NA − + ND ND ND ND ND ND ND ND ND + ND FUNC
c.44T>C p.Ile15Thr Helical bundle N C65 NA + (also in a) − − ND ND ND ND ND ND ND ND − − LOF
c.53T>A p.Met18Lys Helical bundle N C55 NA − (also in a) − − ND ND ND ND ND ND ND ND − ND ND
c.70T>C p.Cys24Arg Zn2+/SiteI C65 NA − − − − − ND ND ND ND − − − − LOF
c.79_80delTGinsGC p.Cys27Ala Zn2+/SiteI C65 NA − − ND ND − ND ND ND ND ND − − − ND
c.83T>C p.Leu28Pro C65 NA + − +/− ND ND ND ND ND ND ND ND + − LOF
c.93C>G p.Ile31Met C0 NA + + + + + ND ND ND ND + ND + + FUNC
c.100C>T p.Pro34Ser C65 NA − − ND ND ND ND ND ND ND ND ND + ND LOF
c.107C>A p.Ser36Tyr β-strand C15 NA + − ND ND ND ND ND ND ND ND ND + ND ND
c.110C>G p.Thr37Arg C65 NA − − − − − ND ND ND ND − + − − LOF
p c.115T>G p.Cys39Gly Zn2+/SiteII C65 NA − − ND ND ND ND ND ND ND ND ND − − LOF
c.121_122delCAinsGC p.His41Ala Zn2+/SiteII C65 NA − − ND ND ND ND ND ND ND ND ND + ND ND
c.124A>G p.Ile42Val C0 NA + + + + + ND ND ND ND + − + + FUNC
c.139T>G p.Cys47Gly Zn2+/SiteI C65 NA − − − ND ND ND ND ND ND ND ND − − LOF
c.143T>G p.Met48Arg Central Helix C35 NA − − ND ND ND ND ND ND ND ND ND − − LOF
c.143T>A p.Met48Lys Central Helix C45 NA + − ND ND ND ND ND ND ND ND ND + ND LOF
q c.190T>G p.Cys64Gly Zn2+/SiteII C65 NA − − − ND − − ND ND ND − ND − ND LOF
r c.190T>C p.Cys64Arg Zn2+/SiteII C65 NA − − ND ND ND ND ND ND ND ND ND − ND LOF
c.206_207delinsTG p.Thr69Met C65 NA − − ND ND ND ND ND ND ND ND ND + ND ND
c.230C>T p.Thr77Met C0 NA + + − ND ND ND ND ND ND ND ND + ND FUNC
c.248T>G p.Val83Gly Helical bundle C C0 NA − + ND ND ND ND ND ND ND ND ND + ND FUNC
c.293G>T p.Gly98Val C65 NA + − ND ND ND ND ND ND ND ND ND + ND LOF
a Prior probability of pathogenicity based on Align GVGD (URL: http://agvgd.iarc.fr/agvgd_input.php): C0 (1%), C15, C25 (29%), C3, C4, C55 (66%), C65 (81%); b Class 1/2,
non-pathogenic/likely non-pathogenic, respectively. Class 4/5, likely pathogenic/ pathogenic, respectively. c [14], d This study, e [37], f [30], g [38], h [39], i [40], l [41], m [42]:
+, the missense variant has no effect on BRCA1 function. −, the missense variant disrupts BRCA1 function. n [43]: −, HDR rescue prediction and/or functional score <0.53, +, HDR rescue
prediction and/or functional score >0.53, assuming 0.53 as the threshold for classifying a variant as functional (HDR prediction score is calculated by combining the Ubiquitin ligase
activity and BARD1 binding functional scores). o [44]: functional classification based on the saturation genome editing (SGE) score. p Predicted splicing affecting the variant. q splicing
affecting variant. r [15]. Abbreviations: NA, not applicable. ND, not done. HDR, homology directed recombination. mESCs, mouse embryonic stem cells. Pred, predicted HDR rescues
score. Func, functional: LOF, loss of function.
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Under inducing conditions, a bright fluorescence was observed in bacterial cells co-expressing
the strong interacting anti-parallel leucine zipper NfrGFP-Z/Z-CfrGFP (ZN/ZC) fusion peptides
and the positive controls (BDN/BR1C, UbN/BR1C). No fluorescence was observed in bacterial cells
co-expressing the non-cognate negative controls (BDN/ZC, UbN/ZC) (Figures 2 and 3). The following
variants of the validation panel showed a fluorescence resembling that of the positive controls:
p.Lys45Gln and p.Asp67Tyr (Class 1), p.Met18Thr (Class 4), p.Thr37Lys and p.His41Arg (Class 5),
while no fluorescent signal was observed for the validation panel variants p.Leu22Ser, p.Cys39Arg,
p.Cys39Tyr, p.Cys44Phe, p.Cys44Ser, p.Cys44Tyr, p.Cys61Gly and p.Cys64Tyr (all class 5). Among the
analyzed VUS, p.Ile15Thr, p.Leu28Pro, p.Ile31Met, p.Ser36Tyr, p.Ile42Val, p.Met48Lys, p.Cys64Gly,
p.Cys64Arg, p.Thr77Met, and p.Gly98Val showed bright fluorescence. Conversely, no fluorescence
was observed in bacteria expressing the variants p.7-10delinsGln, p.Ile15Val, p.Met18Lys, p.Cys24Arg,
p.Cys27Ala, p.Pro34Ser, p.Thr37Arg, p.Cys39Gly, p.His41Ala, p.Cys47Gly, p.Met48Arg, p.Cys64Tyr,
p.Thr69Met., and p.Val83Gly (Figure 2).
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Figure 2. Detection of the BARD1/BRCA1 interaction by the GFP-fragm nt reassembly assay.
Fluorescence was assessed after 24 h of growth at 30 ◦C followe by 2 days of incubation at RT.
All pictures were taken with the same setting of digital camera (long-wave UV light, 365 nm).
[ZN, H6-NfrGFPZ, ZC, ZCfrGFP, BDN, H6-NfrGFPBARD1, BR1C, BRCA1CfrGFP].
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The screening assessing the effect of BRCA1 variants on the binding to UbcH5a revealed bright
fluorescence for bacterial cells co-expressing NfrGFP-UbcH5a together with BRCA1-CfrGFP bearing
the class1 variants p.Lys45Gln and p.Asp67Tyr and the VUS p.Ile31Met, p.Ile42Val, p.Thr77Met,
p.Ile15Val, and Val83Gly in the helical bundle interface (Figure 3). Conversely, all tested class 4 and
class 5 variants were not able to bind to UbcH5a. These results indicate 100% sensitivity and specificity
of this assay. All remaining tested VUS, including some of those that maintained the interaction
with BARD1, namely p.Ile15Thr, p.Leu28Pro, p.Ser36Tyr, and p.Met48Lys, abrogated the binding
with UbcH5a.
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Fluorescence was assessed after 24 h of growth at 30 ◦C followe by 2 days of incubation at RT.
All pictures were aken with the same sett ng of digital camera (long-wave UV light, 365 nm).
[ZN, H6-NfrGFPZ, ZC, ZCfrGFP, UbN, H6-NfrGFPUbcH5a, BR1C, BRCA1CfrGFP].
To confirm that the loss of fluorescence was attributable to the lack of binding to BARD1 and/or
UbcH5a and not to poor expression of the BRCA1 mutants, the cell lysates were visualized by Western
blotting against the GFP tag. The results showed that all fusion peptides were expressed to a similar
extent (Figure 4A).
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2.3. Evaluation of the Effect of the BRCA2 Variants on the Interaction with the DSS1 Protein by the
GFP-Reassembly Assay
The C-terminal region of BRCA2 contains a DSS1/ssDNA Binding Domain (DBD) consisting of
five components. The first is described as the helical domain (HD) due to its 190 amino acids consisting
mainly of α-helices. This is followed by three oligonucleotide/oligosaccharide binding folds (OB1,
OB2 and OB3). In addition, within OB2, a 130 amino acid insertion exists, which was named the
tower domain due to its tower-like structure protruding from the OB fold. The crystallographic study
of BRCA2-DBD revealed a stoichiometric complex with DSS1, which is almost entirely mediated by
highly conserved residues spanning the HD and OB1 motifs. Solely, one DSS1 residue interacts with
the first portion of the OB2 motif [32].
We replaced the leucine zipper peptides in the original constructs (pET11a-NfrGFP-Z and
pMRBAD-Z-CfrGFP) with HD, the three OB motifs, each of which is in a distinct construct and
the protein DSS1 is in all the possible orientations (i.e., pET11a-NfrGFP-HD/OB1/OB2/OB3
pET11a-NfrGFP-DSS1, pMRBAD-HD/OB1/OB2/OB3-CfrGFP, and pMRBAD-DSS1-CfrGFP).
Upon co-transformation in bacterial cells, bright fluorescence was observed only when the HD
and OB1 were fused to the NfrGFP and DSS1 was fused to the CfrGFP while a less pronounced
fluorescence was observed in bacterial cells co-expressing BRCA2-OB2 and DSS1 inserted in the same
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orientation (Figure 5). No fluorescence was detected when the above inserts were fused in the opposite
orientation and co-transfected likely due to a conformational restraint of GFP-reassembly under these
conditions. Consistently with the BRCA2 DBD-DSS1 crystal structure, no fluorescence was observed
in bacteria co-expressing BRCA2-OB3 and DSS1 in either orientation (Figure 5 and Supplemental
Figure S1).
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Figure 5. Detec ion of the DSS1/BRCA2 nteraction by GFP-fragment reassembly assay. Fluorescence
was assessed after 24 h of growth at 30 ◦C followe by 2 days of incubation at RT. All pictures were
taken with the same setting of digital camera (long-wave UV light, 365 nm). [ZN, H6-NfrGFPZ,
ZC, ZCfrGFP, BR2HDN, H6-NfrGFPBRCA2HD, BR2OB1N, H6-NfrGFPBRCA2OB1, BR2OB2N,
H6-NfrGFPBRCA2OB2, BR2OB3N, H6-NfrGFPBRCA2OB3, DSS1C, DSS1CfrGFP].
Based on the above results, we decided to evaluate the effect of the BRCA2 variants mapped to
the gene regions encoding for the HD and OB1 motifs only. All 22 mutants and the corresponding
wild-type forms were co-transformed with the pMRBAD-DSS1-CfrGFP expressing the wild-type DSS1.
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In addition, the pET11a-NfrGFP-HD was co-transformed with the pMRBAD-Z-CfrGFP expressing the
leucine zipper peptide as a non-cognate negative control.
As reported in Figure 5, no fluorescence was observed in bacterial cells co-expressing non-cognate
negative control NfrGFP-HD/Z-CfrGFP (HDN/ZC) while bright fluorescence was detected in
bacteria co-expressing the positive controls ZN/ZC, NfrGFP-HD/DSS1-CfrGFP (HDN/DSS1C),
and NfrGFP-OB1/DSS1-CfrGFP (OB1N/DSS1C). Comparable fluorescence was observed in bacterial
cells co-expressing DSS1-CfrGFP with NfrGFP fused to the BRCA2 peptides bearing all the variants
of Class 1/2 and the following VUS: p.Arg2502His, p.Tyr2543Cys, p.Ser2546Pro, p.Ile2550Thr,
p.Asp2566Glu, and p.Asn2644Asp (HD). No fluorescence was observed in all the bacteria expressing
BRCA2 peptides carrying the Class 4/5 mutations and the VUS p.Phe2562Leu (HD). The expression
level of all the NfrGFP-HD/OB1 peptides was verified by Western blotting analysis using an anti-GFP
antibody and no significant differences were observed (Figure 4B).
2.4. Validation of the GFP-Reassembly Screenings
The re-assembled complexes were purified by Immobilized Metal Affinity Chromatography
(IMAC) from the soluble fraction of co-transformed bacterial cell lysates exploiting the hexahistidine
tag (H6) fused to the N-terminus of the NGFP fragments [14,15]. Equal aliquots of the cleared
lysates of co-transformed E. coli BL21 (DE3) cells were incubated with Ni-NTA agarose resin and the
affinity-captured material was analyzed by Western blotting using a polyclonal anti-GFP antibody
(Supplemental Figures S2–S4). The detection of two bands corresponding to the complex components
confirmed interactions with the binding proteins for all BRCA1 and BRCA2 constructs that tested
positive in the fluorescence reassembly assay. No bands, or bands of very low intensity, were observed
in case BRCA1 and BRCA2 variants for whom no fluorescence was detected, which confirms the
lack of interaction. Assay specificity was supported by the absence of signals detected in cell lysates
co-expressing the NfrGFP-BARD1, NfrGFP-UbcH5a, or the NfrGFP-HD with the CfrGFP-Z peptide
(non-cognate negative controls).
2.5. Evaluation of the Effect of VUS on mRNA Splicing
Exonic variants may affect protein functions not only by altering the amino acid sequence,
but also abolishing naturally-occurring splice sites or introducing/activating new or cryptic splice
sites. To account for this possibility, we performed an in silico analysis on all 30 VUS included in the
study, from which only three were predicted to be spliceogenic by ≥three algorithms of the Alamut
software. These included BRCA1 c.110C>G and c.115T>G, predicted to introduce novel acceptor
splice sites, and BRCA1 c.190T>G, predicted to reinforce the strength of an alternatively used donor
splice site in exon 5. Existing mRNA assay data reports no effect on mRNA splicing for BRCA1
c.110C>G [57], while BRCA1 c.190T>G has been shown to lead to increased levels of a non-productive
naturally-occurring isoform (∆5q) [58], which carries the out of frame deletion of the distal portion of
exon 5 [59]. To the best of our knowledge, no experimental data has been reported as for the c.115T>G.
No spliceogenic effect was predicted for all remaining VUS.
3. Discussion
The reporting of VUS can cause uncertainty and anxiety regarding cancer risk and clinical
management. In addition, appropriate medical care may be delayed for individuals carrying VUS that
are later determined to be pathogenic. In the near future, the relevance of these questions is likely to
rise, as the relative frequency of VUS on the total number of variants identified in HBOC individuals is
expected to increase dramatically with the development of next generation sequencing (NGS) analyses
and the possibility to screen gene panels containing several verified or putative breast/ovarian cancer
predisposition genes at minimal additional costs [60]. Furthermore, a study evaluating the coding
regions and exon-intron boundaries of a 42-cancer gene sequencing panel (including BRCA1 and
BRCA2) identified one or more VUS in approximately 90% of the patients [61]. This underlines
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the need to develop accurate methods to discriminate VUS that are actually related to cancer risk
(pathogenic) from those without clinical relevance (non-pathogenic or benign).
In this study, we evaluated the use of an in vitro protein-fragment complementation assay and
the GFP-fragment reassembly screening for the functional characterization of BRCA1 and BRCA2
VUS. We had previously applied this method to functionally characterize an Italian founder variant
(p.Cys64Arg) mapped to the RING-finger domain of BRCA1 [15]. This variant was shown to abolish
the interaction of BRCA1 with the partner protein BARD1, in a manner similar to the known cancer
predisposing variant p.Cys61Gly [62]. In this case, we applied the same approach to analyze the
effect of 25 BRCA1 VUS mapped to the RING-finger domain on the binding with BARD1 and UbcH5a
proteins and seven BRCA2 VUS mapped to the DBD domain on the binding with the DSS1 protein.
To evaluate the accuracy of the assays in discriminating pathogenic from non-pathogenic variants,
we tested the effect of a panel of 13 BRCA1 and 15 BRCA2 variants (validation panels) previously
classified according to the IARC 5-class system. The assays analyzing the BRCA1/UbcH5a and
BRCA2/DSS1 interactions show 100% sensitivity (percentage of correctly classified pathogenic variants)
and 100% specificity (percentage of correctly classified non-pathogenic variants). In fact, all constructs
carrying the Class 1 and 2 variants included in the validation panels displayed complex formation
with the selected binding partners, while all constructs carrying the Class 4 and 5 variants did not.
Based on these findings, our investigation shows that 19 (18 BRCA1 and 1 BRCA2) VUS behaved as
pathogenic and 11 (5 BRCA1 and 6 BRCA2) as neutral variants (Figures 3 and 5, Tables 3 and 4).
Two issues need to be considered when evaluating the performance of the GFP-fragment
reassembly assay. First, since the assays described are based on an artificial experimental model,
where functional domains of human proteins are expressed in prokaryotic cells, the behavior of mutant
constructs that we observed might not reflect the properties of full-length BRCA proteins expressed
in their ‘natural’ context. However, it must be considered that, although our observations might
actually provide clues for the molecular mechanisms mediating the tumor suppressor activity of BRCA
proteins (see below), the aim of this study was essentially to collect evidence for the clinical relevance
of BRCA VUS by the use of functional assays that efficiently dichotomize variants into pathogenic
or non-pathogenic. Second, some exonic non-synonymous changes can affect gene functionality by
altering mRNA splicing. In a few cases, i.e., when the spliceogenic allele retains the ability to produce
a full-length protein, this occurrence may co-exist with a pathogenic effect of the missense substitution
such as in the case of the BRCA2 c.8168A>G (p.Asp2723Gly) [47,56]. Previous data and in silico
analyses revealed for two of the BRCA1 VUS we tested, an actual (c.190T>G) or potential (c.115T>G)
spliceogenic effect. Based on the outcomes of the BRCA/UbcH5a interaction assay, all the above
variants were predicted to be pathogenic. However, no data are presently available to ascertain if
full-length proteins carrying such variants are actually expressed, and, therefore, no data are present
to hypothesize dual mRNA/protein defects.
The assay analyzing the BRCA1/BARD1 binding reveals high specificity (100%), but lower
sensitivity (62.5%), compared to the assay exploiting BRCA1/UbcH5a interaction, which indicates
that the analyses of different protein-protein interactions may have a different level of accuracy in
predicting the pathogenicity of amino acid changes in binding domains. In fact, the class 4 p.Met18Thr
and the class 5 p.Tyr37Lys and p.His41Arg variants preserved the interaction with BARD1 as the
wild-type protein and the proteins carrying the Class1 variants p.Lys45Gln and p.Asp67Glu.
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c.7469T>C p.Ile2490Thr DBD HD C0 1 + ND ND + ND
c.7544C>T p.Thr2515Ile DBD HD C0 1 + +/− +/− + +
c.7826G>A p.Gly2609Asp DBD HD C65 4 − − ND + −
c.7878G>C p.Trp2626Cys DBD HD C65 5 − − ND − ND
c.7879A>T p.Ile2627Phe DBD HD C15 5 − − − − ND
c.7940T>C p.Leu2647Pro DBD HD C65 4 − − − ND ND
c.7958T>C p.Leu2653Pro DBD HD C65 5 − − − ND ND
c.8063T>C p.Leu2688Pro DBD OB1 C65 4 − − ND − ND
c.8149G>T p.Ala2717Ser DBD OB1 C0 1 + ND ND + +
c.8165C>G p.Thr2722Arg DBD OB1 C65 5 − − − − ND
c.8167G>C p.Asp2723His DBD OB1 C65 5 − − − − ND
c.8168A>G p.Asp2723Gly DBD OB1 C65 5 − − − − ND
c.8187G>T p.Lys2729Asn DBD OB1 C0 1 + + + + +
c.8243G>A p.Gly2748Asp DBD OB1 C65 5 − − − − ND
c.8324T>G p.Met2775Arg DBD OB1 C0 2 + ND ND ND ND
VUS
c.7505G>A p.Arg2502His DBD HD C0 NA + ND ND ND ND
c.7628A>G p.Tyr2543Cys DBD HD C15 NA + ND ND ND ND
c.7636T>C p.Ser2546Pro DBD HD C0 NA + ND ND ND ND
c.7649T>C p.Ile2550Thr DBD HD C25 NA + ND ND ND ND
c.7684T>C p.Phe2562Leu DBD HD C15 NA − − ND ND ND
c.7698T>G p.Asp2566Glu DBD HD C0 NA + ND ND ND ND
c.7930A>G p.Asn2644Asp DBD HD C0 NA + ND ND ND ND
a Prior probability of pathogenicity based on Align GVGD (URL: http://agvgd.iarc.fr/agvgd_input.php): C0 (1%), C15, C25 (29%), C3, C4, C55 (66%), C65 (81%). b Class 1/2:
non-pathogenic/likely non-pathogenic and class 4/5: pathogenic/likely pathogenic. c This study d [45–48], e [45,46], f [49], g [50]: “+”: the missense variant has no effect on BRCA2
function. “−“: the missense variant disrupts BRCA2 function. Abbreviations: DBD, DNA binding domain. HD, helical domain. OB1, oligonucleotide/oligosaccharide binding fold 1.
NA: not applicable. ND: not done. HDR: homology directed repair. mESCs: mouse embryonic stem cell.
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Similar results were observed using alternative approaches in independent studies (Table 3).
Morris and co-workers reported a comprehensive analysis of missense mutations mapped to the
RING-finger domain of BRCA1 and, using yeast 2-hybrid (Y2H) and in vitro ubiquitin ligase assays,
they showed that, in the presence of the p.Met18Thr variant, BRCA1: (a) retains the interaction
with BARD1, (b) is no longer able to bind UbcH5a, and (c) loses the E3 ubiquitin ligase activity [37].
Ransburgh and co-workers exploiting the co-immunoprecipitation approach showed that the variant
p.Met18Thr only modestly affects the interaction between BRCA1 and BARD1 [38]. Moreover, a recent
analysis measuring the effect of approximately 2000 BRCA1 missense substitutions, both on BARD1
binding and E3 ubiquitin ligase activity, reported that the BRCA1 proteins carrying the variants
p.Met18Thr, p.Thr37Lys, and p.His41Arg are able to interact with BARD1 and lose the E3 ligase
activity [43]. All these observations, together with our results, suggest that, in the absence of the
BRCA1-UbcH5a complex, the maintenance of the binding with BARD1 is dispensable for the BRCA1
tumor suppressor activity. Thus, we speculate that the reduced or abrogated E3 ubiquitin ligase activity,
through loss of binding with UbcH5a, is correlated with disease susceptibility and the prediction
of pathogenicity. The observations of Drost and co-workers support this hypothesis, who reported
that mice carrying the pathogenic p.Cys61Gly variant, inactivating BRCA1 E3 ligase activity [37],
are embryonically lethal because of a developmental delay and that, in addition, the latency and
nature of mammary tumors with one Brca1 allele carrying the p.Cys61Gly variant and one Brca1
conditional null allele were similar to those carrying two Brca1 null alleles [63]. Consistently with
these findings, two of the BRCA1 VUS that, in our analysis, did not inhibit the BARD1 interaction,
but lose the UbcH5a, and for which data on enzymatic properties are available (p.Ile15Thr, p.Leu28Pro)
and lack ubiquitin ligase activity [37] (Table 3). However, it has to be mentioned that, in another
study, the missense substitution p.Ile26Ala, abrogating E2 binding and thus ubiquitin-ligase activity,
was found to prevent tumor formation to the same degree as wild-type Brca1 in three conditional
genetic models. Furthermore, the DNA damage response remained intact with no changes in
chromosome stability or sensitivity to genotoxic stress in mouse embryonic fibroblasts [64]. Given the
discrepancy of the results from the two studies, the implication of BRCA1 E3 ligase activity in tumor
suppression remains to be elucidated.
In the presence of p.Thr77Met, BRCA1 is able to bind both BARD1 and UbcH5a proteins.
However, as reported by Morris and co-workers, the proteins lose the ubiquitin ligase activity [37].
A possible explanation is that a weak interaction between BRCA1 and UbcH5a is not sufficient to
promote the ubiquitin ligase activity. Actually, the GFP-fragment reassembly approach can detect
very weak and transient interactions and the fluorescence intensity observed does not necessarily
correlate quantitatively to the interaction affinity of the proteins, which represents a limitation for
this assay. Therefore, hypomorphic variants (i.e., variants weakening, but not completely disrupting,
the interaction of BRCA1 and BRCA2 with partner binding proteins, which retains partial protein
activity) are likely to produce a positive fluorescent signal and can be categorized as non-pathogenic
with this approach. In effect, using the Y2H assay, Morris and co-workers showed a reduction in
binding to the UbcH5a of BRCA1 carrying the p.Thr77Met variant. These observations suggest that
the p.Thr77Met may be a hypomorphic variant associated with moderate-to-low risk of breast and
ovarian cancers. Furthermore, this variant was observed in trans with a pathogenic variant in an
individual without clinical signs of Fanconi anemia (FA) or FA-like disease, which is consistent with
the suggestion that the p.Thr77Met is hypomorphic and is not associated with a high risk of cancer.
Further analyses, using additional approaches such as the Y2H assay and the split biosensor assays
measuring protein interaction kinetics (the tripartite split-GFP association assay [65]), are required to
define the thresholds of binding activity that discriminate between pathogenic and neutral variants
and assess potential intermediate effects.
A series of important considerations have to be applied to functional assays evaluating the BRCA1
and BRCA2 VUS [10,11]. In particular, a panel of different validated assays, representative of different
protein functions, should be used, in order to avoid the misinterpretation of the clinical relevance
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of BRCA gene variants. We observed good correlation of results obtained from the GFP-reassembly
screenings with those of other reported functional assays, including homology-directed repair (HDR),
mouse embryo stem cells (mESCs) viability, and drug resistance assays (Tables 3 and 4). In fact,
BRCA1 and BRCA2 VUS that were proficient in these assays, retain binding activity with UbCH5a
and DSS1, respectively. All variants that were not proficient in other reported assays showed a loss of
the binding activities. These included the BRCA2 p.Phe2562Leu, which is the only VUS that, in our
assay, abolishes the ability of BRCA2 DBD to bind DSS1, which is reported to be deficient in HDR
activity [48].
To date, the most accurate medium throughput functional approaches in evaluating BRCA1 and
BRCA2 VUS are the yeast-cell based colony size phenotype (SCP) assay [40,66] and the HDR assay in
mammalian cells [47,48], respectively (Tables 3 and 4). Compared to the GFP-reassembly screening,
the SCP assay shows lower sensitivity (96%) and specificity (93%). Importantly, contrary to the SCP
assay, the GFP-reassembly screening analyzing the effect of BRCA1 variants on UbcH5a binding
correctly classifies the p.Cys61Gly variant as pathogenic (Table 3). While the GFP-reassembly assay
and the HDR functional assay show the same level of accuracy, the latter is more technically and
experimentally demanding and time consuming.
While this manuscript was in preparation, Findlay and co-workers published the results of a
massive functional characterization of BRCA1 single nucleotide variants, (SNVs) based on a highly
sensitive and specific saturation genome editing (SGE) approach [44]. Findlay et al. measured the
effect on the survival of the near-haploid HAP1 cell line of almost 4,000 SNVs corresponding to 96.5%
of all possible base-pair changes in 13 exons that encode the RING and BRCT domains. The assay
was based on the observation that the maintenance of BRCA1-mediated HDR is necessary for the
viability of HAP1 cells. Notably, we observed a 100% correlation between the functional classification
based on SGE scores and the outcomes of our GFP-reassembly assay evaluating the BRCA1/UbCH5a
interaction (Table 3). This strict consistency suggests that BRCA1/UbCH5a interaction, which mediates
BRCA1 ligase activity, is essential for proficient HDR. In addition, since HDR deficiency is targeted by
drugs exploiting synthetic lethality, such as Poly (ADP-ribose) polymerase 1 (PARP1) inhibitors [67],
our assay could be used to predict a response to therapeutic treatments.
SGE has demonstrated to be a viable and highly productive strategy for functionally classifying
thousands of variants in clinically actionable genes such as BRCA1, including a large number of
variants that, to date, have not been observed in humans. In fact, a major strength of this approach
is represented by the possibility of examining variants located throughout the entire gene sequence,
while, on the contrary, the GFP-reassembly assay may be applied only to gene regions coding
for protein-interaction domains. However, it must be noted that the vast majority of pathogenic
BRCA gene variants lie in these domains [6,51]. On the other hand, SGE analyses are limited by the
extreme difficulty of generating all possible gene variants that may occur in patients. In particular,
substitutions and insertions/deletions involve more than one nucleotide. For example, in our study,
we could analyze three variants identified in families referred for BRCA gene testing, namely the
BRCA1 c.20_29del9 (p.7-10delinsGln) and c.206_207delCCinsTG (p.Thr69Met) in frame deletions,
and the c.107C>A (p.Ser36Tyr) SNV, that were not evaluated in the high-throughput study of Findlay
and co-workers.
This represents an important and attractive advantage of the split-GFP reassembly in vitro method,
which, together with its easiness of use and robustness, makes it suitable for routine analyses of
naturally occurring genetic variants. Moreover, this assay could be applied to large-scale studies that
are required to achieve robust estimates of the accuracy of functional approaches for VUS classification
and clinical applicability.
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4. Materials and Methods
4.1. Variant Selection
All examined variants were observed in high risk HBOC families fulfilling the ascertainment
criteria for BRCA1/2 testing in use at the collaborating institutions, including the Fondazione IRCCS
Istituto Nazionale dei Tumori (Milan, Italy) [68], the Catalan Institute of Oncologia (Hospitalet de
Llobregat, Barcelona, Spain) [69], and the Rigshospitalet (Copenhagen, Denmark) [70].
4.2. Plasmid Construction
The pET11a-NfrGFP-Z, pMRBAD-Z-CfrGFP, pET11a-NfrGFP-BARD1, and pMRBAD-BRCA1-
CfrGFP expression vectors were obtained and generated as previously described [14]. The BRCA2
fragments encoding the Helical Domain (HD, amino acids 2480–2667), three oligonucleotide-binding
folds (OB1, amino acids 2668–2807, OB2, amino acids 2808–3048, OB3, amino acids 3050–3185),
the full-length coding sequences of the DSS1, and the UbcH5a genes were obtained by PCR
amplification of cDNA prepared from 293T cells using a RevertAid H Minus First Strand cDNA
Synthesis Kit (Thermo Scientific, Waltham, MA, USA), and cloned into pET11a-NfrGFP-Z between
XhoI and BamHI restriction sites (HD, OB1, OB2, OB3, DSS1, and UbcH5a), and pMRBAD-Z-CfrGFP
between NcoI and AatII restriction sites (HD, OB1, OB2, OB3, and DSS1) after removing the leucine
zipper motifs (Z). All of the BRCA1 and BRCA2 variants were obtained by direct mutagenesis
of pMRBAD-BRCA1-CfrGFP and of pET11a-NfrGFP-BRCA2HD/OB1 using the QuickChange XL
Site-directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA), according to the manufacturer’s
instruction. DNA sequencing (Eurofins Genomics, Ebersberg, Germany) technology checked the
recombinant clones.
4.3. Expression of Recombinant Peptides
E. coli BL21 (DE3) cells were transformed with pET11a-NfrGFP vector series or pMRBAD-CfrGFP
vector series. Single colonies were picked and used to inoculate 20 mL of LB broth medium containing
100 µg/mL of ampicillin (pET11a-NfrGFP vector series, Addgene, Watertown, MA, USA) or 35 µg/mL
of kanamycin (pMRBAD-CfrGFP vector series, Addgene, Watertown, MA, USA). The colonies were
then incubated at 37 ◦C until the Optical Density measured at a wavelength of 600 nm (OD600) reached
0.6. Then, induction of recombinant peptides was carried out with the addition of IPTG to a final
concentration of 20 µM (pET11a-NfrGFP vector series) and 0.2% of L-arabinose (pMRBAD-CfrGFP
vector series). After growing for 24 h at 30 ◦C followed by two days at room temperature (RT), the cells
were harvested by centrifugation. Each pellet was resuspended in 1 mL of lysis buffer [50 mM Tris-HCl,
300 mM NaCl, 0.1% v/v Triton X-100, 100 µM EDTA pH8.0, 0.5 mg/mL lysozime, 20 mM Imidazole,
protease inhibitors (0.5 mM PMSF, 0.4 µg/mL leupeptin, 0.5 µg/mL aprotinin), and 5 µg/mL DNase
and RNase]. The resuspended cells were lysed by sonication. The cell debris were removed by
centrifugation at 4 ◦C for 20 min at 13,000 rpm. The protein concentration of the whole cell extracts was
determined by the Bradford method [71], using the Bio-Rad protein assay kit (Bio-Rad Laboratories,
Hercules, CA, USA). Equal amounts of protein (20 µg) were subjected to 13% SDS-PAGE and visualized
by Western blotting using an anti-GFP antibody (# 600-101-215, Rockland, Limerik, PA, USA).
4.4. GFP-Fragment Reassembly Screening
E. coli BL21 (DE3) cells were co-transformed with the following compatible pairs
of plasmids: pET11a-NfrGFP-Z and pMRBAD-Z-CfrGFP, pET11a-NfrGFP-BARD1,
or pET11a-NfrGFP-UbcH5a and pMRBAD-BRCA1-CfrGFP (both as wild-type or mutant forms),
pET11a-NfrGFP-BRCA2HD/OB1/OB2/OB3, or pMRBAD-BRCA2HD/OB1/OB2/OB3-CfrGFP (both
as wild-type or mutant forms) and pMRBAD-DSS1-CfrGFP or pET11a-NfrGFP-DSS1, and screened for
the occurrence of GFP-fragment reassembly, as previously described [14]. Fluorescence was observed
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after excitation with long-wave (365 nm) UV light combined with the short pass (SP) emission filter
using a Syngene image capture system (SYNGENE, Cambridge, UK), as specified by the manufacturer.
4.5. Purification of the Reassembled GFP Complexes
The H6-NfrGFP-BARD1(or UbcH5a)/BRCA1-CfrGFP (both as wild-type or mutant forms) and
H6-NfrGFP-BRCA2HD/OB1 (both as wild-type or mutant forms)/DSS1-CfrGFP complexes were
purified from the soluble fraction of co-transformed E. coli strain BL21 (DE3) by IMAC using nickel
nitrilotriacetic (Ni-NTA) agarose resin (QIAGEN, Hilden, Germany), according to the manufacturer’s
instruction. The protein complexes were subjected to 13% SDS-PAGE and visualized by Western
blotting using a polyclonal anti-GFP antibody (# 600-101-215, Rockland).
4.6. Protein Structures
The 3D crystallographic structures of the BRCA1-BARD1 heterodimeric complex and of BRCA2
in complex with the protein DSS1 were represented by the Swiss-PdbViewer tool (SPDBV, URL:
http://www.expasy.org/spdbv/, accessed on 7 May 2015) [72] using the pdb as a template (protein
data bank, URL: http://www.pdb.org, accessed on 7 May 2015) [73] files 1JM7 and 1MJE, respectively.
4.7. In Silico Analyses
The Alamut Visual version 2.10 (Interactive Biosoftware, Rouen, France) was used to evaluate the
possible effect of examined VUS on mRNA transcript splicing.
5. Conclusions
The concordance between genetic data and the functional assays analyzing the BRCA1/UbcH5a
and the BRCA2/DSS1 interactions, observed for the validation panels of previously classified variants,
strongly suggests that the approaches described in the present study are able to differentiate between
VUS that either inactivate or have no effect on BRCA1 and BRCA2 functions and support their utility
in the assessment of the clinical relevance of VUS. Caution is warranted when the interpretation of
VUS is based only on results from an assay focusing on a single specific biochemical activity. Therefore,
these assays should be used in combination with other evidence when assessing variant pathogenicity,
and the efficacy will be further verified using larger validation panels.
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